Acucela said the underwriters of its initial public offering in Japan will sell 9.2 million shares at $17.65 apiece, raising about $143 million after expenses and discounts. Seattle biotechnology company Acucela said the underwriters of its initial public offering in Japan will sell 9.2 million shares at $17.65 apiece, raising about $143 million after expenses and discounts. The shares, which are not available to U.S. investors and won’t be traded here, have been approved for listing on the the Mothers market of the Tokyo Stock Exchange, Acucela said in a regulatory filing.
Help employers find you! Check out all the jobs and post your resume.
